Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
暂无分享,去创建一个
M. Rozman | J. Bladé | L. Rosiñol | M. Cibeira | M. Cid | X. Filella | M. Segarra | E. Lozano
[1] P. Sonneveld,et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Michael L. Wang,et al. Lenalidomide Plus High-Dose Dexamethasone Provides Improved Overall Survival Compared to High-Dose Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma (MM): Results of 2 Phase III Studies (MM-009, MM-010) and Subgroup Analysis of Patients with Impaired Renal Function. , 2006 .
[3] J. Zeldis,et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone Alone as Primary Therapy for Newly Diagnosed Multiple Myeloma. , 2006 .
[4] D. Ribatti,et al. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma , 2006, Oncogene.
[5] Christian Jakob,et al. Angiogenesis in multiple myeloma. , 2006, European journal of cancer.
[6] Jason McCoy,et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] D. Ribatti,et al. Bone marrow angiogenesis in multiple myeloma , 2006, Leukemia.
[8] P. Ravaud,et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] D. Chauhan,et al. Cytokines and signal transduction. , 2005, Best practice & research. Clinical haematology.
[10] J. S. San Miguel,et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. , 2005, Blood.
[11] G. Tricot,et al. Immunomodulatory drugs in multiple myeloma , 2005, Expert opinion on investigational drugs.
[12] Hartmut Goldschmidt,et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.
[13] K. Podar,et al. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. , 2005, Blood.
[14] F. B. Sørensen,et al. Syndecan‐1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival , 2005, British journal of haematology.
[15] K. Zervas,et al. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro‐vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma , 2004, Hematological oncology.
[16] M. Silva,et al. Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma , 2004, European journal of haematology.
[17] R. Kyle,et al. Drug therapy: Multiple myeloma , 2004 .
[18] Santhosh K. P. Kumar,et al. Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy , 2004, Bone Marrow Transplantation.
[19] J. Esteve,et al. Response to thalidomide in multiple myeloma: impact of angiogenic factors. , 2004, Cytokine.
[20] Y. Ikeda,et al. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment , 2004, Pathology international.
[21] Santhosh K. P. Kumar,et al. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma , 2004, Leukemia.
[22] R. Fonseca,et al. Plasma levels of tumour necrosis factor alpha and interleukin‐6 predict progression‐free survival following thalidomide therapy in patients with previously untreated multiple myeloma , 2003, British journal of haematology.
[23] D. Ribatti,et al. Vascular endothelial growth factor and its receptors in multiple myeloma , 2003, Leukemia.
[24] G. Morgan,et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.
[25] W. Berdel,et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. , 2003, Blood.
[26] D. Kyriakou,et al. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: Correlation with markers of disease activity , 2003, American journal of hematology.
[27] R. Fonseca,et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. , 2003, Blood.
[28] J. Cavenagh,et al. Thalidomide in multiple myeloma: current status and future prospects , 2003, British journal of haematology.
[29] R. Fonseca,et al. Bone marrow angiogenesis in multiple myeloma: effect of therapy , 2002, British journal of haematology.
[30] Sung-Bae Kim,et al. Comparison of Microvessel Density Before and after Peripheral Blood Stem Cell Transplantation in Multiple Myeloma Patients and Its Clinical Implications: Multicenter Trial , 2002, International journal of hematology.
[31] R. Fonseca,et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] P. Hahnfeldt,et al. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. , 2002, Journal of the National Cancer Institute.
[33] A. Ogata,et al. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma , 2002, British journal of haematology.
[34] J. Folkman,et al. Angiogenesis-dependent diseases. , 2001, Seminars in oncology.
[35] H. Goldschmidt,et al. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion , 2001, British journal of haematology.
[36] S. Rajkumar,et al. Angiogenesis in multiple myeloma. , 2001, Seminars in oncology.
[37] N. Munshi,et al. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. , 2001, Seminars in oncology.
[38] P. Brousset,et al. Increased vascularization in myeloma. , 2001 .
[39] K. Wernecke,et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma , 2001, European journal of haematology.
[40] H. Goldschmidt,et al. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[41] M. Dietel,et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma , 2000, Annals of Hematology.
[42] R. Fonseca,et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[43] W. Berdel,et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. , 2000, Blood.
[44] B. Barlogie,et al. Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.
[45] N. Raje,et al. Thalidomide--a revival story. , 1999, The New England journal of medicine.
[46] D. Ribatti,et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. , 1999, Blood.
[47] T. Grogan,et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. , 1999, Cancer research.
[48] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.
[49] J. Rossi,et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .
[50] B. Klein,et al. Interleukin-6 in human multiple myeloma. , 1995, Blood.
[51] A. Waage,et al. TNF and IL‐6 are potent growth factors for OH‐2, a novel human myeloma cell line , 1994, European journal of haematology.
[52] D. Ribatti,et al. Bone marrow angiogenesis and progression in multiple myeloma , 1994, British journal of haematology.
[53] R. D'Amato,et al. Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[54] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[55] Shaji K. Kumar,et al. Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma. , 2006, Haematologica.
[56] D. Ribatti,et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. , 2006, Cancer research.
[57] J. Esteve,et al. Extramedullary multiple myeloma escapes the effect of thalidomide. , 2004, Haematologica.
[58] P. Richardson,et al. Thalidomide: emerging role in cancer medicine. , 2002, Annual review of medicine.
[59] Mike Clarke,et al. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.